trending Market Intelligence /marketintelligence/en/news-insights/trending/q730lr-segjtn1aoaz-eeq2 content esgSubNav
In This List

Corcept Therapeutics sues Teva over alleged therapy patent infringement

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Corcept Therapeutics sues Teva over alleged therapy patent infringement

Corcept Therapeutics Inc. filed a lawsuit against Teva Pharmaceutical Industries Ltd., alleging infringement of patents related to its hormone therapy Korlym.

The lawsuit was filed in the U.S. District Court for the District of New Jersey in response to Teva's submission of an application with the U.S. Food and Drug Administration to market a generic version of Korlym, which is also known as mifepristone.

Korlym is used to treat Cushing's syndrome, a rare disease caused by the excess production of the hormone cortisol, which can result in upper-body obesity along with thinning of the arms and legs and high blood sugar.

Korlym, Corcept's first FDA-approved medication, has been commercially available since April 2012.